UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday (June 18) that it has received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global and Aspen Pharmacare (JSE: APN), South Africa’s largest drugmaker. A period of exclusivity has been agreed with Aspen and GSK will respond to the offer subject to consultation with employees and the relevant works councils.
The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra (fondaparinux sodium) and Fraxiparine (nadroparin) - excluding China, India and Pakistan - brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees. Media reports suggest the deal size would be in the $700-$900 million range. The proposed transaction is aligned to GSK’s strategy of focusing on products with the most growth potential and the delivery of its pipeline, the UK firm said.
Assets originally acquired from Sanofi
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze